^
    Back
    Association details:
    Biomarker:EGFR mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:luminespib (AUY922) (HSP90 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer

    Excerpt:
    ...- All patients must have pathologic evidence of advanced lung adenocarcinoma (stage IIIB or stage IV) confirmed histologically/cytologically at NU, MSKCC, or DFCI and EITHER previous RECIST-defined response (CR or PR) to an EGFR-TKI (erlotinib or gefitinib) or an investigational EGFR TK inhibitor OR a documented mutation in the EGFR gene (G719X, exon 19 deletion, L858R, L861Q)...
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations

    Excerpt:
    ...Patients must have EGFR gene mutation in their tumors....
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    AUY922 in Patient With Stage IV NSCLC

    Excerpt:
    ...- EGFR mutations in exon 20 T790M....
    Trial ID:
    NCT01922583
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR

    Excerpt:
    ...Median Progression Free and Overall Survival`The Number of Participants With Treatment Related Serious Adverse Events`Exon 20 EGFR Mutations Among Participants That Responded to Treatment...
    Trial ID:
    NCT01854034
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.

    Excerpt:
    ...- Patients enrolled to the fifth stratum, modified EGFR mutant, must have documented prior response to EGFR TKI as defined by CR, PR or SD for 6 months or greater unless patient has de novo resistance to EGFR TKI (e.g....
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Ann Oncol
    Title:

    PHASE II ACTIVITY OF THE HSP90 INHIBITOR AUY922 IN PATIENTS WITH ALK-REARRANGED (ALK+) OR EGFR-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

    Excerpt:
    Pts with advanced NSCLC who progressed following ≥1 prior line of chemotherapy, received AUY922 (70 mg/m2 ) as a once-weekly, 1-hr infusion….Clinical activity of AUY922 was seen in pts with ALK+ and EGFR-mut NSCLC, with partial responses in 6/21 (29%) pts and 7/35 (20%) pts, respectively...
    DOI:
    10.1093/annonc/mds395